PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
Acta Materia Medica · 2022
DOI: 10.15212/amm-2021-0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Materia Medica, 2022. Verfasst von Hiroyuki Inuzuka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Neurodegenerative diseases are characterized by the progression of neuronal degeneration, resulting in dysfunction of cognition and mobility. Many neurodegenerative diseases are due to proteinopathies arising from unusual protein accumulation and aggregation. The aggregation of misfolded proteins, such as β-amyloid, α-synuclein, tau, and polyglutamates, is a hallmark of Alzheimer’s disease (AD). These aggregated proteins are undruggable targets and usually do not respond to conventional small-molecule agents. Therefore, developing novel technologies and strategies for decreasing the levels of protein aggregates is critical for the treatment of AD. Recently, the emerging proteolysis targeting chimera (PROTAC) technology has been considered for artificial, selective degradation of aberrant target proteins. These engineered bifunctional molecules engage target proteins, which are then degraded either by the cellular degradation machinery via the ubiquitin-proteasome system or through the autophagy-lysosome degradation pathway. Although PROTAC technology is preferable to oligonucleotides and antibodies for the treatment of neurodegenerative diseases, many limitations, such as their pharmacokinetic properties, tissue distribution, and cell permeability, must be addressed. Herein, we review recent advances in PROTAC technology, as well as PROTACs’ limitations, for the pharmaceutical targeting of aberrant proteins involved in AD. We also review the therapeutic potential of dysregulated signaling, such as the PI3K/AKT/mTOR axis, for the management of AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Förderung
- NCI NIH HHS
Zitieren
APA
Inuzuka, H., Liu, J., Wei, W., & Rezaeian, A. H. (2022). PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives. Acta Materia Medica. https://doi.org/10.15212/amm-2021-0001
Vancouver
Inuzuka H, Liu J, Wei W, Rezaeian AH. PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives. Acta Materia Medica. 2022. doi:10.15212/amm-2021-0001
BibTeX
@article{Inuzuka2022,
author = {Inuzuka, Hiroyuki and Liu, Jing and Wei, Wenyi and Rezaeian, Abdol-Hossein},
title = {PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives},
journal = {Acta Materia Medica},
year = {2022},
doi = {10.15212/amm-2021-0001}
}
EUVIMED